Vico Therapeutics
Gene therapy company developing treatments for rare neurological diseases using antisense oligonucleotide (ASO) technology, with a focus on spinocerebellar ataxias and other CNS disorders.
Website
https://www.vicotx.comLocation
Leiden, Netherlands
Founded
2017
Investors
1
Categories
biotech, gene-therapy, rare-disease, antisense, neurology
Notes
Vico Therapeutics is a gene therapy company developing treatments for rare neurological diseases using antisense oligonucleotide (ASO) technology. The company is headquartered in Leiden, Netherlands.
The company's ASO platform is designed to target the underlying genetic causes of rare neurological diseases, including:
- Spinocerebellar ataxias (SCAs)
- Huntington's disease
- Other repeat expansion disorders
ASOs can modulate gene expression by binding to specific RNA sequences, offering potential disease-modifying treatments for conditions that currently have no effective therapies.
Vico is backed by Polaris Partners.
Team
- Dinko Valerio, Ph.D. - Co-founder & Chief Executive Officer
- LinkedIn: linkedin.com/in/dinkovalerio
Additional Research Findings
- Portfolio company of Polaris Partners
- Focus on rare neurological diseases
- Antisense oligonucleotide platform
- Spinocerebellar ataxia programs
- Leiden, Netherlands headquarters
- Founded in 2017
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Polaris Partners | US | biotech-focused | - | 33 |